newsfilter
← Latest News
Business Wire·

Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information

  • Robbins LLP is investigating Sionna Therapeutics for potential securities law violations & fiduciary duty breaches by officers & directors.
  • Sionna Therapeutics stock dropped 92% on August 10, 2026, to close at $4.51 following disappointing Phase 2a results for SION-719.
  • The PreciSION CF trial failed to meet its primary endpoint of reducing sweat chloride levels when SION-719 was combined with Trikafta.
  • Despite having substantial financial resources at the end of the second quarter, the company plans to preserve capital while determining the future of its clinical pipeline.
  • Shareholders who incurred losses may contact attorney Aaron Dumas, Jr. via email or phone to inquire about the investigation on a contingency fee basis.
  • Robbins LLP, founded in 2002, has recovered over $1 billion for shareholders through litigation & governance improvements.
  • Investors can sign up for Stock Watch to receive alerts regarding class action settlements or executive misconduct.